Novin Genome (NG) Lab, Research and Development Center for Biotechnology, Shahrekord, Iran.
Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
BMC Cancer. 2024 Mar 25;24(1):377. doi: 10.1186/s12885-024-12124-w.
The primary aim of this study is to critically evaluate and comment on the research presented in the article titled "A Novel Super-Enhancer-Related Gene Signature Predicts Prognosis and Immune Microenvironment for Breast Cancer" by Wu et al. Our specific objectives include assessing the methodology employed by the authors, particularly in regard to the utilization of a super-enhancer-related gene signature for breast cancer prognosis prediction. We propose the necessity of subgroup analysis to effectively address the heterogeneity in breast cancer subtypes, which is crucial for the applicability of the SERGs across diverse breast cancer cases. Additionally, we suggest conducting a more comprehensive immune panel study to deepen the understanding of how the immune microenvironment impacts breast cancer prognosis. Our commentary seeks to provide valuable insights into the strengths and weaknesses of the study, contributing to a more comprehensive understanding of its findings and potential clinical implications.
本研究的主要目的是批判性地评估和评论 Wu 等人撰写的题为“一种新型的超级增强子相关基因标志物可预测乳腺癌的预后和免疫微环境”的文章中呈现的研究。我们的具体目标包括评估作者所采用的方法，特别是在利用超级增强子相关基因标志物进行乳腺癌预后预测方面。我们提出有必要进行亚组分析，以有效地解决乳腺癌亚型的异质性问题，这对于 SERGs 在不同乳腺癌病例中的适用性至关重要。此外，我们建议进行更全面的免疫面板研究，以深入了解免疫微环境如何影响乳腺癌的预后。我们的评论旨在提供对该研究的优势和劣势的有价值的见解，有助于更全面地理解其研究结果和潜在的临床意义。
